Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review

A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming.

News & Events

Landmark Australian influenza collaboration finalist for Eureka Prize

Infectious disease researchers who used a decade of scientific evidence to advocate for a nationwide childhood influenza immunisation policy have earned a finalist position at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.

News & Events

Meningococcal vaccine provides extra protection for bubs

In 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.

News & Events

The Kids researcher awarded Research Translation Projects grant

A new research project aims to demonstrate how influenza vaccination in children could be a highly cost-effective health care intervention in Australia.

News & Events

Extra whooping cough shots to protect bubs

An extra whooping cough vaccination for babies comes as a result of work by researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases.

News & Events

Free vaccination public seminar

Immunisation plays an important role in preventing disease within our community. Join us at a FREE public seminar on vaccinations.

Research

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine

A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.

Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.

Research

Whooping Cough

Whooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.